Related Experiment Video

Updated: Jun 27, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Complete response of recurrent squamous cell carcinoma of the lung: dose the dose matter?

Sanghoon Shin, Kwang Joo Kim, Young Joo Lee

    Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
    |December 20, 2008
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
    08:17

    Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

    Published on: June 7, 2015

    Related Experiment Videos

    Last Updated: Jun 27, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
    08:17

    Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

    Published on: June 7, 2015

    Related Concept Videos

    Dose-Response Relationship: Overview01:03

    Dose-Response Relationship: Overview

    Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...

    Articles linked to this work by shared authors, journal, and citation graph.

    Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.

    Lung cancer (Amsterdam, Netherlands)·2026

    Structural basis and preclinical efficacy of MG1124, a novel CEACAM1-targeting antibody synergizing with PD-1 blockade.

    Molecular cancer therapeutics·2026

    Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Advances in Pathology: Journal of Thoracic Oncology 20th Anniversary Series.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Brief Report: Validation of the Sybil Lung Cancer Risk Prediction Model in a Predominantly Black Screening Cohort.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Gene-Specific Analysis of Clonal Hematopoiesis Identifies the Association between ASXL1 and Lung Cancer Risk.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Comparative outcomes of advanced medical rescue therapies in steroid-refractory acute severe ulcerative colitis: a systematic review and network meta-analysis.

    Frontiers in gastroenterology (Lausanne, Switzerland)·2026

    Feasibility and Acceptability of Remote Symptom Monitoring and Wearable Activity Monitoring in Head and Neck Cancer Patients: A Mixed Methods Pilot Study.

    Head & neck·2026

    Early multimodal vasopressor strategy in septic shock: results of the TRICYCLE randomized controlled trial.

    Critical care (London, England)·2026

    Long-term outcomes of prophylactic cardioprotection in early-stage breast cancer patients on non-anthracycline anti-HER2 therapy.

    Cardio-oncology (London, England)·2026

    Continuous infusion of granulocyte colony-stimulating factor is associated with an advantage in neutrophil recovery in pediatric oncologic disorders.

    Cancer chemotherapy and pharmacology·2026

    Ciprofloxacin beyond antibacterial therapy: pharmacological mechanisms, anticancer activity, and translational limitations.

    Naunyn-Schmiedeberg's archives of pharmacology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us